Results 281 to 290 of about 157,671 (305)
Some of the next articles are maybe not open access.
Current opinion in investigational drugs (London, England : 2000), 2001
AstraZeneca (formerly Zeneca) is developing ZD-9331, a non-polyglutamatable thymidylate synthase inhibitor, as a potential treatment for solid tumors and other neoplasia, including colorectal tumors [216476,179954,179955]. ZD-9331 is being developed as both an oral and an i.v.
openaire +1 more source
AstraZeneca (formerly Zeneca) is developing ZD-9331, a non-polyglutamatable thymidylate synthase inhibitor, as a potential treatment for solid tumors and other neoplasia, including colorectal tumors [216476,179954,179955]. ZD-9331 is being developed as both an oral and an i.v.
openaire +1 more source
Current opinion in investigational drugs (London, England : 2000), 2001
ZD-0892, a neutrophil elastase inhibitor, is under development by AstraZeneca as a potential treatment for chronic obstructive pulmonary disease (COPD) and peripheral vascular disease (PVD). It is in phase I clinical trials for these two indications [315489].
openaire +1 more source
ZD-0892, a neutrophil elastase inhibitor, is under development by AstraZeneca as a potential treatment for chronic obstructive pulmonary disease (COPD) and peripheral vascular disease (PVD). It is in phase I clinical trials for these two indications [315489].
openaire +1 more source
Impact of a five-dimensional framework on R&D productivity at AstraZeneca
Nature Reviews Drug Discovery, 2018Dean G Brown +2 more
exaly
AstraZeneca – Forschungsschwerpunkt Infektionskrankheiten
DMW - Deutsche Medizinische Wochenschrift, 2014openaire +1 more source